ANXA3 and cancer: TKIs resistance. In a microarray analysis testing the sensitivity of 45 different cancer cell lines to anticancer tyrosine kinase inhibitors (TKIs) targeting the ERBB/RAS pathway, ANXA3 was indicated to be associated with resistance against multiple TKIs including gefitinib, sorafenib, sunitinib, and lapatinib (Pénzváltó et al., 2013).